Valuation: Quest PharmaTech Inc.

Market Cap 4.23M 3.01M 2.63M 2.43M 2.23M 290M 4.3M 28.98M 11.37M 142M 11.3M 11.06M 488M P/E 2025
-3.29x
P/E 2026 1.18x
Enterprise Value 5.21M 3.71M 3.24M 2.99M 2.75M 357M 5.3M 35.74M 14.02M 175M 13.94M 13.63M 602M EV / Sales 2025
-
EV / Sales 2026 -
Free-Float
83.12%
Yield 2025 *
-
Yield 2026 -
1 day+25.00%
1 month-28.57%
3 months-16.67%
6 months-28.57%
Current year-28.57%
1 week 0.02
Extreme 0.02
0.02
1 month 0.02
Extreme 0.02
0.04
Current year 0.02
Extreme 0.02
0.04
1 year 0.02
Extreme 0.02
0.05
3 years 0.02
Extreme 0.015
0.1
5 years 0.02
Extreme 0.015
0.16
10 years 0.02
Extreme 0.015
0.32
Manager TitleAgeSince
Chief Executive Officer - 17/06/2004
Director of Finance/CFO - 01/01/2005
Director TitleAgeSince
Director/Board Member - 17/06/2004
Chairman - 05/07/2021
Director/Board Member - 05/07/2021
Date Insider Type Main position Quantity % Market Cap.
12-12OtherCompany 0 0%
21/10/25Other

Chief Executive Officer

300,000 0.1774%
21/10/25Other

Chief Executive Officer

1,000,000 0.5913%
Change 5-day change 1-year change 3-year change Capi.($)
+25.00%0.00%-28.57%-73.68% 3.01M
-0.17%+1.47%+3.16%+7.43% 50.35B
-0.42%-2.93%+387.21%+592.28% 39.32B
+0.45%+2.20%+32.08%-5.92% 34.69B
+1.65%+2.95%+15.23%+57.04% 34.08B
+1.68%-1.40%+4.23%+27.34% 26.63B
+0.47%-4.04% - - 16.49B
-0.37%+0.11%+70.31%+115.30% 15.31B
+0.43%+3.34%+14.96%+17.98% 13.8B
+0.97%+2.13%+16.09%-31.03% 12.87B
Average +2.95%-0.36%+57.19%+78.53% 24.35B
Weighted average by Cap. +0.43%-0.32%+82.01%+122.20%

Financials

2025 2026
Net sales - -
Net income -1.8M -1.28M -1.12M -1.03M -951K -123M -1.83M -12.34M -4.84M -60.3M -4.81M -4.71M -208M 5M 3.56M 3.11M 2.87M 2.64M 342M 5.08M 34.26M 13.44M 167M 13.36M 13.07M 577M
Net Debt 795K 566K 495K 456K 420K 54.45M 809K 5.45M 2.14M 26.61M 2.13M 2.08M 91.73M 986K 702K 613K 566K 520K 67.51M 1M 6.76M 2.65M 33M 2.63M 2.58M 114M
Logo Quest PharmaTech Inc.
Quest PharmaTech Inc. is a Canada-based biopharmaceutical company. The Company is developing products to improve the quality of life. The Company is also developing a proprietary MAb AR 9.6 targeting truncated MUC16 as theranostic agents for cancer. The Company has a 42.5% ownership interest in OncoQuest Inc. (OncoQuest), a Canadian biotechnology company developing combinatorial immunotherapy products for the treatment of cancer. OncoQuest’s technology platform included a panel of tumor antigen-specific monoclonal antibodies of the immunoglobulin G (IgG) and E (IgE) class targeting CA125, MUC1, PSA, Her2/neu, CA 19.9 and TAG72; and the application of combinatorial immunotherapy to enhance tumor specific immunity and clinical outcome. The Company also has a 23% ownership interest in OncoVent Co., Ltd. (OncoVent), which is developing antibody-based immunotherapeutic products for cancer for the Greater China territory.
Employees
-
Date Price Change Volume
14/07/26 CA$0.0250 +25.00% 19,600
10/07/26 CA$0.0200 -20.00% 155,100
09/07/26 CA$0.0250 0.00% 1,600